育龄期(≤45岁)乳腺癌患者新辅助化疗中的胸肌面积减少
本研究纳入52例≤45岁原发性乳腺癌患者,在新辅助化疗前后通过乳腺MRI测量胸肌面积(PMA),发现化疗后PMA显著下降(9.6±2.6 cm² vs. 8.7±2.2 cm²,p<0.001),但ΔPMA与临床病理特征及RECIST反应无显著相关;PMA评估的观察者间和观察者内一致性良好。
要点
- 乳腺MRI可定量测量胸肌面积,用于监测新辅助化疗期间的肌肉质量变化。
- 年轻乳腺癌患者新辅助化疗后胸肌面积显著减少,但变化幅度与肿瘤反应无关。
- PMA测量的一致性良好(观察者间k=0.74),适合临床重复评估。
诊断标准与关键数值
- 新辅助化疗前PMA均值9.6±2.6 cm²,化疗后均值8.7±2.2 cm²,p<0.001,delta值1.41。
- PMA评估观察者间一致性k=0.74,观察者内一致性分别为0.67和0.73。
- 根据RECIST标准,完全缓解与部分缓解之间无显著差异。
临床应用与阅片要点
- 在乳腺MRI复查时,可于轴位3D FLASH预对比T1加权图像上测量胸肌面积,辅助评估肌肉质量变化。
- PMA测量需注意观察者间和观察者内一致性良好,但应规范测量层面和范围。
局限性
- 单中心研究,样本量有限(52例)。
- 未报告ΔPMA与临床病理特征及RECIST反应间的显著相关性,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Loss of muscle mass is associated with negative clinical outcome in breast cancer (BC) patients. Therefore, the aim of the study is to evaluate if there is pectoralis muscle area (PMA) depletion, reflecting loss of muscle mass, in breast cancer patients of reproductive age (≤ 45 years) undergoing neoadjuvant chemotherapy (NAC) and to correlate PMA with clinical and histopathological data.
MATERIAL AND METHODS: This monocentric study, approved by our institutional review board, enrolled a total of 52 consecutive patients (mean age 37 ± 4.96 years) with histologically proven primary breast cancer between January 2019 and September 2021, treated with NAC and in whom tumor response and PMA were assessed with breast MRI. Two radiologists calculated PMA before and after NAC independently and blindly on axial 3D FLASH pre-contrast T1-weighted images. Wilcoxon-Mann-Whitney U test compared median values and percentage changes of pectoralis muscle area at the beginning and at the end of NAC (158 ± 25.5 days). Multivariate regression analysis on ΔPMA (difference between PMA pre-NAC and PMA post-NAC) was done according to clinical and histopathological data. Inter-reader and intra-reader agreement was estimated with K statistics.
RESULTS: Pre-NAC PMA mean value was larger than post-NAC PMA mean value (9.6 ± 2.6 cm2 vs. 8.7 ± 2.2 cm2, p < 0.001, delta value 1.41). According to the RECIST criteria, no significant differences between complete and partial response were found. Multivariate regression analysis did not show any significant relationships between ΔPMA and age, time between MRI examinations, estrogen and progesterone receptor status, human epidermal growth factor receptor 2 status, Ki-67 expression, lymph node involvement, RECIST criteria, histological type, and different regimes of NAC. Inter-reader (k = 0.74) and intra-reader agreement (0.67 and 0.73) in PMA assessment was good.
CONCLUSIONS: PMA variation in BC young patients, directly estimated on breast MRI, could be a potential tool to monitor body composition during NAC with potential implications in improving outcome.
引用
- Rossi, Lambertini, Brunetti, et al. Muscle mass loss in breast cancer patients of reproductive age (≤ 45 years) undergoing neoadjuvant chemotherapy. Radiol Med. 2022. PMID: 36536266. doi:10.1007/s11547-022-01574-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。